EPROSARTAN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Eprosartan, and when can generic versions of Eprosartan launch?
Eprosartan is a drug marketed by Pharmobedient and is included in one NDA.
The generic ingredient in EPROSARTAN is eprosartan mesylate. There are eleven drug master file entries for this compound. Additional details are available on the eprosartan mesylate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for EPROSARTAN?
- What are the global sales for EPROSARTAN?
- What is Average Wholesale Price for EPROSARTAN?
Summary for EPROSARTAN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | EPROSARTAN at DailyMed |
US Patents and Regulatory Information for EPROSARTAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmobedient | EPROSARTAN MESYLATE | eprosartan mesylate | TABLET;ORAL | 202012-001 | Nov 16, 2011 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Pharmobedient | EPROSARTAN MESYLATE | eprosartan mesylate | TABLET;ORAL | 202012-002 | Nov 16, 2011 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
